Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $509.8 million.

  • Organogenesis Holdings' Liabilities and Shareholders Equity rose 14.24% to $509.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 7.09%. This contributed to the annual value of $497.9 million for FY2024, which is 8.23% up from last year.
  • Organogenesis Holdings' Liabilities and Shareholders Equity amounted to $509.8 million in Q3 2025, which was up 10.56% from $461.1 million recorded in Q2 2025.
  • Organogenesis Holdings' 5-year Liabilities and Shareholders Equity high stood at $509.8 million for Q3 2025, and its period low was $319.2 million during Q1 2021.
  • Over the past 3 years, Organogenesis Holdings' median Liabilities and Shareholders Equity value was $460.0 million (recorded in 2023), while the average stood at $463.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 64.24% in 2021, then decreased by 3.53% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $443.3 million in 2021, then increased by 1.38% to $449.4 million in 2022, then increased by 2.37% to $460.0 million in 2023, then increased by 8.23% to $497.9 million in 2024, then climbed by 14.24% to $509.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $509.8 million for Q3 2025, versus $461.1 million for Q2 2025 and $467.4 million for Q1 2025.